HATTR-PN

Clinical trials for HATTR-PN explained in plain language.

Never miss a new study

Get alerted when new HATTR-PN trials appear

Sign up with your email to follow new studies for HATTR-PN, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Our safety recommendation!

By submitting, you agree to our Terms of use

Trials to join now! 1

New hope for rare nerve disease: phase 3 trial of nucresiran begins

Disease control Recruiting now

This study tests a new medicine, nucresiran, for people with a rare inherited disease that damages nerves (hATTR-PN). About 125 adults will receive either nucresiran or another drug (vutrisiran) to see which better slows nerve damage and improves quality of life. The goal is to c…

Matched conditions: HATTR-PN

Phase: PHASE3 • Sponsor: Alnylam Pharmaceuticals • Aim: Disease control

Last updated May 17, 2026 15:00 UTC

HATTR-PN

Get alerted when new HATTR-PN trials appear

New hope for rare nerve disease: phase 3 trial of nucresiran begins